# Iparomlimab and tuvonralimab

Source: https://onco.cc/drugs/iparomlimab-tuvonralimab/  
OnCo record `iparomlimab-tuvonralimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy.

## Summary

Iparomlimab and tuvonralimab (QL1706) uses Qilu's MabPair platform to produce an anti-PD-1 and a short-half-life anti-CTLA-4 antibody in a single manufacturing run. The NMPA approved it in September 2024 for recurrent or metastatic cervical cancer that had failed platinum-based chemotherapy, the first dual checkpoint product approved for this cancer. Phase 3 trials in lung and liver cancers continue.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: PSB205
- Tags: china; nmpa-approved
- Code: QL1706
- Modality: Bifunctional antibody mixture: anti-PD-1 and anti-CTLA-4
- Mechanism: Two antibodies made in one cell line and given as a fixed mixture: a PD-1 blocker with a normal half-life and a CTLA-4 blocker engineered to clear quickly, so the double checkpoint blockade comes with less of the toxicity seen with ipilimumab combinations.
- Approvals: CN 2024: Recurrent or metastatic cervical cancer after platinum chemotherapy

## Sources

- ClinicalTrials.gov: trials of QL1706: https://clinicaltrials.gov/search?intr=QL1706

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/iparomlimab-tuvonralimab.json